Popular Articles

United We Stand; Divided We Fall - Novel Insight On Bacterial Communication
In the July 15th issue of Genes & Development, Dr. Roberto Kolter (Harvard Medical School) and colleagues make the unprecedented observation of paracrine signaling during Bacillus subtilis biofilm formation.
buy viagra
NUVIGIL Is Available For The Treatment Of Excessive Sleepiness Associated With Treated Obstructive Sleep Apnea, Shift Work Disorder And Narcolepsy
Cephalon, Inc. (Nasdaq: CEPH) today announced that NUVIGIL® (armodafinil) Tablets [C-IV], a longer-lasting formulation of modafinil, is now available. NUVIGIL is indicated to improve wakefulness throughout the day for the millions of patients who struggle with excessive sleepiness associated with treated obstructive sleep apnea, shift work sleep disorder, also known as shift work disorder, and narcolepsy. Cephalon has finalized the commercialization plans for NUVIGIL and, beginning today, any patient with a NUVIGIL prescription should be able to obtain the medication from their pharmacy or have it filled within 24 hours.
News of the day
Reps. Ryan, DeLauro To Introduce Bill To Reduce Need For Abortion
Reps. Tim Ryan (D-Ohio) and Rosa DeLauro (D-Conn.) on Thursday will be joined by leaders of the Planned Parenthood Federation of America and NARAL Pro-Choice America in announcing the latest version of a bill that aims to reduce the need for abortion by preventing unintended pregnancies, among other measures, Time reports (Sullivan, Time, 7/23). Ryan and DeLauro first introduced a version of the bill in 2006 (Crary, AP/San Francisco Chronicle, 7/22). However, this version "represents a dramatic break from nearly four decades" of political debate since Roe v. Wade, as both conservative antiabortion-rights groups and abortion-rights advocates have expressed support, according to Time (Time, 7/23).The bill would increase support for comprehensive sex education programs, improve access to contraception, expand Medicaid family planning coverage, increase programs for pregnant or parenting college students, and expand adoption assistance. The Congressional Budget Office has not yet conducted a cost-analysis of the bill, the AP/San Francisco Chronicle reports (AP/San Francisco Chronicle, 7/22). In developing the bill, Ryan sought the help of Rachel Laser, director of culture programs at the policy and strategy think-tank Third Way. According to Time, Laser worked with advocates on both sides and modified the bill to help gather their support, while preventing the measure from becoming "uselessly watered down or split into two."DeLauro noted, "We had to reach a level of trust" with people on both sides and allow them time to become more receptive to the bill"s goals, adding, "Because so often this issue has been one about which there was nothing other than trying to score political points." DeLauro said she hopes the Obama administration will look to the bill for guidance as it crafts its strategy for reducing the need for abortion and preventing unintended pregnancies. President Obama is expected to make an announcement about the plan next month, according to Time (Time, 7/23).DeLauro and Ryan also noted that Rahm Emanuel, Obama"s chief of staff, endorsed an earlier version of the bill when he served in the House, which they hope could mean that Obama would support their measure. DeLauro said, "This is a bill that seems to mesh with the president"s interests," adding, "I see no reason why the White House could not endorse it."Joshua DuBois, director of the White House Office of Faith-Based and Neighborhood Partnerships, said the administration is still reviewing the information it has gathered in recent meetings with representatives on both sides of the abortion debate.Laurie Rubiner, director of Planned Parenthood"s Washington, D.C., office, said "This isn"t a radical bill," adding, "It only seems radical because it"s been so long that we could have a constructive conversation ... with both pro-choice and anti-choice groups around the table."The Rev. Joel Hunter -- an antiabortion-rights evangelical pastor in Orlando, Fla., who serves on the White House Faith-Based Advisory Council -- called the bill "a landmark bill for the culture wars -- a prototype for how we can approach things in the future." He said the bill"s strengths were in its appeals to both liberal and conservative beliefs, adding, "When you realize you need someone who"s been an adversary to help you advance your own projects, that"s a big deal" (AP/San Francisco Chronicle, 7/22).
Mental Health

ImmunoCellular Therapeutics Announces Filing Of Key Patent Application Relating To Cancer Stem Cell Technology

ImmunoCellular Therapeutics, Ltd. (OTC: IMUC.OB) (IMUC), a biotechnology company, announced the filing of a provisional U.S. patent application relating to its novel vaccine technology targeting cancer stem cells. The patent application relates to new peptide candidates that may significantly expand the potential target patient population for the company"s cancer stem cell vaccine product candidate, ICT-121. Many cancer therapies are limited by their ability to be used only in patients with certain human leukocyte antigen (HLA) types. Identification of the new peptides for use in IMUC"s vaccine should enable the use of IMUC"s product candidate in patients with many different HLA types. The Company currently has 25 issued or pending patents. "This patent application supports our broad and growing portfolio of intellectual property. ICT-121 is an immunotherapy that targets cancer stem cells - a very exciting approach given the product"s mission of destroying cancer cells at their root as well as its proven ability in preclinical studies to be highly targeted for destroying cancer cells," stated Manish Singh, Ph.D., president and chief executive officer of IMUC. "This product may have applicability to multiple types of cancer, but our first clinical target will be glioblastoma. We anticipate filing an Investigational New Drug (IND) application next quarter to begin a Phase I clinical trial of ICT-121." About ICT-121 ICT-121 is IMUC"s cancer stem cell (CSC) vaccine product candidate that consists of a peptide to stimulate a cytotoxic T-lymphocyte (CTL) response to CD133, which is generally overexpressed on the CSCs. It is designed as an "off-the-shelf" vaccine. IMUC will initially evaluate it in a Phase I clinical study for glioblastoma which the company expects to file an IND for in the third quarter of this year. While glioblastoma will be the initial target for ICT-121, CD133 is also overexpressed in colon cancer, breast cancer, liver cancer, prostate cancer, multiple myeloma and melanoma, providing many potential cancer targets for this CSC vaccine in the future. ImmunoCellular Therapeutics, Ltd.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):